Cargando…
Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young
OBJECTIVE: Misdiagnosis of maturity-onset diabetes of the young (MODY) remains widespread, despite the benefits of optimized management. This cross-sectional study examined diagnostic misclassification of MODY in subjects with clinically labeled young adult-onset type 1 and type 2 diabetes by extend...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357216/ https://www.ncbi.nlm.nih.gov/pubmed/22432108 http://dx.doi.org/10.2337/dc11-1243 |
_version_ | 1782233638237110272 |
---|---|
author | Thanabalasingham, Gaya Pal, Aparna Selwood, Mary P. Dudley, Christina Fisher, Karen Bingley, Polly J. Ellard, Sian Farmer, Andrew J. McCarthy, Mark I. Owen, Katharine R. |
author_facet | Thanabalasingham, Gaya Pal, Aparna Selwood, Mary P. Dudley, Christina Fisher, Karen Bingley, Polly J. Ellard, Sian Farmer, Andrew J. McCarthy, Mark I. Owen, Katharine R. |
author_sort | Thanabalasingham, Gaya |
collection | PubMed |
description | OBJECTIVE: Misdiagnosis of maturity-onset diabetes of the young (MODY) remains widespread, despite the benefits of optimized management. This cross-sectional study examined diagnostic misclassification of MODY in subjects with clinically labeled young adult-onset type 1 and type 2 diabetes by extending genetic testing beyond current guidelines. RESEARCH DESIGN AND METHODS: Individuals were selected for diagnostic sequencing if they displayed features atypical for their diagnostic label. From 247 case subjects with clinically labeled type 1 diabetes, we sequenced hepatocyte nuclear factor 1 α (HNF1A) and hepatocyte nuclear factor 4 α (HNF4A) in 20 with residual β-cell function ≥3 years from diagnosis (random or glucagon-stimulated C-peptide ≥0.2 nmol/L). From 322 with clinically labeled type 2 diabetes, we sequenced HNF1A and HNF4A in 80 with diabetes diagnosed ≤30 years and/or diabetes diagnosed ≤45 years without metabolic syndrome. We also sequenced the glucokinase (GCK) in 40 subjects with mild fasting hyperglycemia. RESULTS: In the type 1 diabetic group, two HNF1A mutations were found (0.8% prevalence). In type 2 diabetic subjects, 10 HNF1A, two HNF4A, and one GCK mutation were identified (4.0%). Only 47% of MODY case subjects identified met current guidelines for diagnostic sequencing. Follow-up revealed a further 12 mutation carriers among relatives. Twenty-seven percent of newly identified MODY subjects changed treatment, all with improved glycemic control (HbA(1c) 8.8 vs. 7.3% at 3 months; P = 0.02). CONCLUSIONS: The systematic use of widened diagnostic testing criteria doubled the numbers of MODY case subjects identified compared with current clinical practice. The yield was greatest in young adult-onset type 2 diabetes. We recommend that all patients diagnosed before age 30 and with presence of C-peptide at 3 years' duration are considered for molecular diagnostic analysis. |
format | Online Article Text |
id | pubmed-3357216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-33572162013-06-01 Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young Thanabalasingham, Gaya Pal, Aparna Selwood, Mary P. Dudley, Christina Fisher, Karen Bingley, Polly J. Ellard, Sian Farmer, Andrew J. McCarthy, Mark I. Owen, Katharine R. Diabetes Care Original Research OBJECTIVE: Misdiagnosis of maturity-onset diabetes of the young (MODY) remains widespread, despite the benefits of optimized management. This cross-sectional study examined diagnostic misclassification of MODY in subjects with clinically labeled young adult-onset type 1 and type 2 diabetes by extending genetic testing beyond current guidelines. RESEARCH DESIGN AND METHODS: Individuals were selected for diagnostic sequencing if they displayed features atypical for their diagnostic label. From 247 case subjects with clinically labeled type 1 diabetes, we sequenced hepatocyte nuclear factor 1 α (HNF1A) and hepatocyte nuclear factor 4 α (HNF4A) in 20 with residual β-cell function ≥3 years from diagnosis (random or glucagon-stimulated C-peptide ≥0.2 nmol/L). From 322 with clinically labeled type 2 diabetes, we sequenced HNF1A and HNF4A in 80 with diabetes diagnosed ≤30 years and/or diabetes diagnosed ≤45 years without metabolic syndrome. We also sequenced the glucokinase (GCK) in 40 subjects with mild fasting hyperglycemia. RESULTS: In the type 1 diabetic group, two HNF1A mutations were found (0.8% prevalence). In type 2 diabetic subjects, 10 HNF1A, two HNF4A, and one GCK mutation were identified (4.0%). Only 47% of MODY case subjects identified met current guidelines for diagnostic sequencing. Follow-up revealed a further 12 mutation carriers among relatives. Twenty-seven percent of newly identified MODY subjects changed treatment, all with improved glycemic control (HbA(1c) 8.8 vs. 7.3% at 3 months; P = 0.02). CONCLUSIONS: The systematic use of widened diagnostic testing criteria doubled the numbers of MODY case subjects identified compared with current clinical practice. The yield was greatest in young adult-onset type 2 diabetes. We recommend that all patients diagnosed before age 30 and with presence of C-peptide at 3 years' duration are considered for molecular diagnostic analysis. American Diabetes Association 2012-06 2012-05-11 /pmc/articles/PMC3357216/ /pubmed/22432108 http://dx.doi.org/10.2337/dc11-1243 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Research Thanabalasingham, Gaya Pal, Aparna Selwood, Mary P. Dudley, Christina Fisher, Karen Bingley, Polly J. Ellard, Sian Farmer, Andrew J. McCarthy, Mark I. Owen, Katharine R. Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young |
title | Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young |
title_full | Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young |
title_fullStr | Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young |
title_full_unstemmed | Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young |
title_short | Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young |
title_sort | systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357216/ https://www.ncbi.nlm.nih.gov/pubmed/22432108 http://dx.doi.org/10.2337/dc11-1243 |
work_keys_str_mv | AT thanabalasinghamgaya systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT palaparna systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT selwoodmaryp systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT dudleychristina systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT fisherkaren systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT bingleypollyj systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT ellardsian systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT farmerandrewj systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT mccarthymarki systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung AT owenkathariner systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung |